drugset
drugset / Trial / NCT05236868

A Study of JNJ-42847922 (Seltorexant) in Healthy Participants

NCT05236868 ↗

Phase 1 Completed 10 enrolled Janssen Research & Development, LLC
NaSingle-groupOpen-labelOther

Summary

The purpose of this study is to determine the absolute bioavailability of seltorexant in healthy participants following a single oral dose of seltorexant and an intravenous (IV) infusion dose of 14C-seltorexant.

Timeline

Start
2022-02-03
Primary completion
2022-03-01
Completion
2022-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Seltorexant Small molecule — Oral

Indications

No indication recorded.